BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2025; 31(47): 114651
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114651
Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease
Gabriel Heymann, Saumik Rahman, Daniel Kats, Bubu A Banini, Srinivas Gaddam, Elise Aslanian, Sarpong Boateng, Gary Israel, Thiruvengadam Muniraj
Gabriel Heymann, Sarpong Boateng, Department of Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT 06606, United States
Saumik Rahman, Gary Israel, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06510, United States
Daniel Kats, Department of Medicine, Brown University, Providence, RI 02912, United States
Bubu A Banini, Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, United States
Srinivas Gaddam, Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States
Elise Aslanian, Section of Digestive Disease, Yale School of Medicine, New Haven, CT 06510, United States
Thiruvengadam Muniraj, Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, United States
Author contributions: Muniraj T and Heymann G had full access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis; Heymann G, Rahman S, Kats S, Banini BA, Gaddam S, Aslanian H, Boateng S, Israel G, and Muniraj T are responsible for the study concept and design, acquisition of data, analysis and interpretation of data and drafting of the manuscript.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Yale University.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Thiruvengadam Muniraj, MD, Department of Medicine, Yale University School of Medicine, 333 Cedar Street, 1080 LMP, New Haven, CT 06520, United States. thiruvengadam.muniraj@yale.edu
Received: September 26, 2025
Revised: October 19, 2025
Accepted: November 3, 2025
Published online: December 21, 2025
Processing time: 85 Days and 15.6 Hours
Core Tip

Core Tip: Non-alcoholic fatty pancreas disease (NAFPD) and metabolic dysfunction-associated steatotic liver disease (MASLD) are commonly co-occurring disorders associated with metabolic dysregulation with important clinical implications. Few studies have examined the relationship between these conditions in terms of disease severity. We perform a retrospective analysis of patients with biopsy-proven MASLD, and non-contrast enhanced abdominal computed tomography to assess how NAFPD correlates with degrees of hepatic steatosis, steatohepatitis, and hepatic fibrosis. We find that most patients with MASLD met criteria for NAFPD, but the degree of pancreatic steatosis did not portend a greater degree of hepatic steatosis, steatohepatitis, or hepatic fibrosis.